Ceftal

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ceftal

What is Ceftal?

Ceftal is a pharmaceutical medication classified as a cephalosporin antibiotic. It is specifically categorized as a third-generation cephalosporin, a group of drugs known for their broad-spectrum activity against various types of bacteria.

Mechanism of Action

The primary function of Ceftal is to interfere with the way bacteria build their protective cell walls. By binding to specific proteins within the bacterial cell membrane, the medication prevents the cross-linking of peptidoglycan, which is a vital component of the cell wall structure. Without a stable cell wall, the bacteria cannot withstand osmotic pressure, leading to the eventual rupture and death of the bacterial cell. This process is known as bactericidal action.

General Characteristics

Ceftal is designed to address infections caused by both Gram-positive and Gram-negative bacteria. Its chemical structure makes it particularly effective against many organisms that have developed resistance to earlier generations of antibiotics, such as certain strains of penicillin-resistant bacteria.

Unlike many other antibiotics that are administered orally, Ceftal is typically formulated for parenteral administration, meaning it is delivered directly into the body through clinical methods such as intravenous or intramuscular routes. This allows the medication to reach therapeutic levels in the bloodstream and tissues quickly.

Therapeutic Use

As an antibacterial agent, Ceftal is used to manage a wide range of systemic and localized infections. Its broad reach allows it to be utilized in various clinical settings where bacterial pathogens are suspected or confirmed. It is important to note that Ceftal is strictly intended for the treatment of bacterial infections and has no effect on viral infections, such as the common cold or influenza.

Regulatory References

  1. Cefuroxime Drug Information (MedlinePlus)

What side effects are possible with Ceftal?

Possible Side Effects and Safety Information

The safety profile for Ceftal (Cefuroxime) is defined by officially documented adverse reactions classified by frequency and affected body systems, derived from regulatory labeling.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized based on their documented occurrence:

  • Common (ge1/100 to <1/10): Candida overgrowth, headache, dizziness, diarrhea, nausea, vomiting, and transient increases in hepatic enzyme levels.
  • Uncommon (ge1/1,000 to <1/100): Positive Coombs' test, leukopenia, thrombocytopenia, skin rashes, and transient increase in bilirubin.
  • Not Known: Severe reactions such as anaphylaxis, seizures, haemolytic anaemia, pseudomembranous colitis, and Severe Cutaneous Adverse Reactions (SCARs).

System-Organ-Class Groupings

Side effects are officially grouped into System-Organ-Classes (SOCs), including Gastrointestinal Disorders, Nervous System Disorders, and Blood and Lymphatic System Disorders. Transient elevations of liver enzymes are classified under Hepatobiliary Disorders.


Serious Adverse Reactions and Safety Notes

Regulatory documents highlight the risk of serious adverse reactions, including potentially fatal Anaphylactic Reactions and Clostridioides difficile-Associated Diarrhea (CDAD). CDAD can be reported to occur up to two months following the administration of antibacterial agents. Prolonged use may lead to the overgrowth of non-susceptible organisms. The medicine is formally contraindicated in patients with a known hypersensitivity to the active substance or to other beta-lactam antibacterial drugs (e.g., penicillins).


Population-Specific Considerations

Official safety notes specify that the elimination of the active substance is slower in individuals with Renal Impairment. The oral suspension formulation is noted to contain phenylalanine, which is a consideration for pediatric patients with phenylketonuria (PKU).

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory prescribing information for Ceftal (Cefuroxime) indicates that an overdose may lead to severe neurological sequelae stemming from cerebral irritation caused by high serum concentrations of the drug. Documented clinical signs of severe toxicity include encephalopathy, convulsions (seizures), and coma.


Official Guidance on Emergency Action

Immediate medical attention is required upon suspicion of overdose or the onset of severe symptoms. Governmental health guidance specifies that emergency services must be contacted immediately if the affected person collapses, has a seizure, has trouble breathing, or cannot be awakened.

The overdose risk is also explicitly linked to impaired drug clearance in certain populations: symptoms can occur if the dose is not reduced appropriately in patients with renal impairment.


Management and Antidote Status

No specific antidote is explicitly documented in the regulatory information to reverse the effects of Cefuroxime overdose. Management is symptomatic and supportive. However, official regulatory labels state that high serum levels of Cefuroxime can be reduced by haemodialysis and peritoneal dialysis.

Therapeutic Uses of Ceftal

What Ceftal Treats: Main Uses and Benefits

Ceftal is applied across domains where additional symptomatic support is needed to manage specific symptom clusters. It is commonly used in the management of symptoms related to bacterial infections across domains like the lungs, skin and soft tissue, and the urinary tract. The medication provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.


Key Therapeutic Focus

Ceftal is relevant when supportive symptom management is appropriate for conditions characterized by periods of heightened symptoms. It helps address symptom clusters that may become intense or disruptive, such as symptoms related to physical discomfort, those associated with inflammatory or irritative states. The medication is commonly used to help with symptomatic relief in acute episodes involving the respiratory, skin, and urinary systems.


Quick Fact: Support for Symptomatic Discomfort

Quick Fact: Support for Symptomatic Discomfort in the urinary and respiratory tracts. This medication is relevant for easing symptoms like burning during urination or throat/sinus pain, and contributes to easing the overall symptom load when symptoms are more noticeable.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Ceftal?

This section describes the population eligibility and non-eligibility criteria for Ceftal (Cefuroxime) as strictly defined in official governmental regulatory documentation.


Populations for Whom Use is Contraindicated

Category Regulatory Status
Allergy to Cephalosporins Absolute Prohibition
Allergy to Ceftal (Cefuroxime) Absolute Prohibition
Severe Immediate beta-Lactam Allergy History Absolute Prohibition

Ceftal must not be used by patients with a known hypersensitivity to the active substance, to any cephalosporin antibiotic, or a history of severe immediate allergic reaction to any other beta-lactam antibacterial agent (such as penicillins).


Restricted and Conditional Eligibility

Certain populations are eligible for use only under specific conditions documented in the official labeling:

  • Renal Impairment: Use is restricted and requires adjustment from the standard dosage, as the drug's elimination is dependent on kidney function.
  • Infants Under 3 Months: Use is generally not established or not recommended for oral formulations due to insufficient clinical data.
  • Pregnancy and Lactation: Use is conditional upon a formal assessment that the benefit to the patient outweighs any potential risk. Cefuroxime is known to be excreted in breast milk.
  • History of Colitis: Use requires caution and close monitoring due to the potential risk associated with antibiotic-induced gastrointestinal conditions.

What should I know about interactions with other medicines?

The interaction profile for Ceftal (Cefuroxime) is primarily defined by its effects on pharmacokinetics and pharmacodynamics, according to government regulatory information. No specific drug-drug combination is formally labeled as contraindicated in the major regulatory summaries.


Exposure-Modifying Interactions

The substance Probenecid increases Cefuroxime's systemic exposure by inhibiting its renal tubular secretion, which prolongs the drug's half-life and increases its peak concentration. Conversely, drugs that reduce gastric acidity, including H2-Antagonists, Proton Pump Inhibitors (PPIs), and antacids, reduce the bioavailability of the oral form (Cefuroxime axetil). Due to this reduction in exposure, co-administration with H2-Antagonists and PPIs should generally be avoided.

A specific timing rule is mandated for short-acting antacids: oral Cefuroxime axetil must be taken at least one hour before or two hours after the antacid. Furthermore, the absorption of oral Cefuroxime axetil is officially enhanced when taken with food.


Pharmacodynamic and Procedural Constraints

Ceftal introduces pharmacodynamic constraints when used with certain medicines. Co-administration with oral anticoagulants may be associated with an increase in the International Normalized Ratio (INR). Additionally, Cefuroxime may decrease the effectiveness of some oral contraceptives. A procedural constraint exists regarding laboratory glucose tests, where Cefuroxime can interfere with copper-reduction methods (leading to false-positive results) and ferricyanide tests (leading to false-negative results).

Mechanism of Action

Covalent Inhibition of Bacterial Cell Wall Enzymes

Ceftal's mechanism centers on the covalent inhibition of key bacterial enzymes known as Penicillin-Binding Proteins (PBPs). The molecule forms a stable bond with the PBP active site, permanently blocking the transpeptidation process required to build the rigid bacterial cell wall. This molecular action results in structural failure, causing the physiological consequence of bacterial cell death.


Cascade to Osmotic Cell Lysis and Bacterial Destruction

The blocked cell wall construction initiates a destructive cascade. The compromised cell wall cannot withstand the internal osmotic pressure, causing the cell to rupture (lysis), often facilitated by the activation of bacterial autolytic enzymes. This cascade defines the core bactericidal effect, resulting in the destruction of the bacterial cells via lysis.


Structural Resistance to Enzymatic Hydrolysis

A key feature of the drug is its intrinsic structural resistance against many beta-lactamase enzymes, which are bacterial defense proteins. The drug’s structure allows it to maintain the beta-lactam ring integrity against these enzymes, promoting interaction with PBP targets. Mechanistic boundaries include limitations such as bacterial acquisition of mutated PBPs or production of advanced enzymes like ESBLs, which may preclude the drug's action.

Dosage and Administration Information

How Ceftal is used: Official Instructions

Ceftal (Cefuroxime) must be administered strictly according to official instructions, which define the standardized route, dosage, frequency, and specific intake conditions. The medicine is available for oral use (Cefuroxime axetil tablets or suspension) and for parenteral use (Cefuroxime sodium powder for injection for IV or IM administration).

Dosage and Frequency

For adults and adolescents, the dosage and frequency are standardized:

  • Oral Dosing: Most common regimens require 250 mg to 500 mg to be taken twice daily (every 12 hours).
  • Parenteral Dosing (IV/IM): The standard dose for injection is 750 mg given every 8 hours. For severe infections, the dose may be increased to 1.5 g every 8 hours, or 1.5 g every 6 hours by the intravenous route.
  • Duration: Treatment duration typically ranges from 7 to 10 days for many infections, although specific regimens like Early Lyme Disease can extend to 20 days.

Administration Conditions

Administration Rule Official Instruction
Oral Suspension Must be taken with food (e.g., milk or milk products).
Oral Tablets May be taken with or without food. Tablets must be swallowed whole.
Substitutability The tablet and oral suspension are not bioequivalent and cannot be substituted on a milligram-for-milligram basis.
Missed Dose If a dose is missed, take it as soon as remembered. If it is nearly time for the next scheduled dose, skip the missed dose, and return to the regular schedule.

Population Adjustments (Renal Function)

Official instructions require dosage adjustment in patients with impaired renal function to compensate for slower excretion. For marked impairment (creatinine clearance 10-20 mL/min), the standard parenteral dose is reduced to once every 12 hours, and for patients on hemodialysis, a supplemental dose is required after each session.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ceftal

The information below summarizes the clinical research and scientific studies that have evaluated the active ingredient in Ceftal (Cefuroxime). This overview focuses on the types of trials conducted, the outcomes measured by researchers, and the limitations or uncertainties documented in the scientific literature. It is descriptive and does not offer clinical advice or recommendations.


Evidence for Use in Respiratory Tract Infections (Upper and Lower)

Research exploring Ceftal for infections like sore throat (pharyngitis/tonsillitis), acute sinus infections, and lung infections (pneumonia and bronchitis) mainly consists of Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. These studies primarily compared Ceftal's active component to either a placebo or to other established antibiotics.

Researchers used these trials to look for measurements of outcomes related to physical discomfort, which describe how symptoms changed over the study period. They also monitored outcomes reflecting bacteriological status. The collected data studies report how symptoms evolved in the observed populations following treatment completion. However, evidence describing how symptoms evolved in the observed populations for certain conditions has been reported as findings were mixed when compared to a control. Overall, follow-up durations for these studies were limited, meaning long-term effects are not fully established regarding the durability of the effect.


Evidence for Use in Urinary Tract Infections

Ceftal was studied for its use in uncomplicated urinary tract infections (UTIs) through RCTs and comparative trials against other treatments. The research focused on outcomes linked to inflammatory or irritative states, specifically research examining temporary physiological imbalance. A key outcome researchers monitored was the bacteriological eradication of the organisms causing the infection.

Studies reported patterns observed in the measurements of symptom change over the typical 7- to 10-day treatment period. Research highlights changes measured during the study period following administration for susceptible strains. However, the available research base includes many older studies, and comparative evidence is lacking when assessing performance against current patterns of antibiotic resistance. Therefore, certainty remains low for some aspects of its contemporary use, and data are still emerging.

Frequently Asked Questions (FAQ)

Common questions about Ceftal (FAQ)


Q: How quickly does Ceftal start working?

Studies on the active component of Ceftal indicate that it typically reaches its highest concentration in the blood approximately two to three hours after taking the oral form. This timing reflects when the medicine is available in the body for its intended effect.


Q: How long does Ceftal stay in your system?

Ceftal's active component is primarily eliminated from the body by the kidneys. Its elimination half-life in adults with normal kidney function is usually described as about 1 to 2 hours. This measure indicates the time it takes for the concentration of the medicine in the bloodstream to decrease by half.


Q: Does Ceftal cause fatigue or sleepiness?

Official safety documents list effects on the nervous system such as dizziness and headache as Common adverse reactions. Less frequent effects like sleepiness or somnolence have been reported in post-marketing data, but are not listed in the higher frequency categories.


Q: Is a rash a serious side effect of Ceftal?

The official safety profile reports general skin rashes as an Uncommon side effect. However, the medicine also includes a safety warning for Severe Cutaneous Adverse Reactions (SCARs), which are rare but serious and generally described as requiring prompt medical evaluation.


Q: What is the regulatory information about using Ceftal during pregnancy?

Official documentation states that the use of Ceftal during pregnancy is conditional. It requires a formal medical assessment to determine that the potential benefit to the patient outweighs any potential risk. The medicine’s active substance is known to be excreted in breast milk.


Q: Does Ceftal interact with supplements like iron or calcium?

Regulatory documents state that certain substances, such as antacids (which often contain calcium) and other medicines that reduce stomach acidity, can reduce the absorption of oral Ceftal. For this reason, their co-administration should be discussed with a medical professional, as specific timing may be needed.


Q: How is the effectiveness of Ceftal measured in studies?

The effectiveness of Ceftal in clinical trials is primarily measured by two main factors. Researchers look for the resolution of symptoms associated with the infection, as well as the elimination (eradication) of the susceptible bacteria causing the infection, which is confirmed through laboratory testing.


Q: Can Ceftal be crushed or split?

Official instructions for the oral tablets require them to be swallowed whole and not crushed, chewed, or split. This requirement is in place to ensure the proper absorption of the medication, which is necessary for its effectiveness.


Q: Does Ceftal interact with blood pressure medication?

There is no general interaction listed with blood pressure medications. However, the injectable (parenteral) formulation of Ceftal contains a significant amount of sodium, which is a factor relevant for medical professionals treating patients with conditions like hypertension (high blood pressure) or congestive heart failure.


Q: Are there any common foods to avoid while taking Ceftal?

Official documentation does not list specific common foods that must be avoided. However, regulatory instructions specify that the oral suspension form must be taken with food, such as milk or milk products, to assist the medicine's proper absorption.


Q: What is the difference between Ceftal and Cefix?

Ceftal (Cefuroxime) is officially classified as a second-generation cephalosporin antibiotic. Cefix (Cefixime), on the other hand, is generally classified as a third-generation cephalosporin. This classification is based on differences in their core chemical structure, spectrum of activity, and resistance profile.


Q: Why do doctors prescribe Ceftal instead of other options?

Ceftal is often utilized because it belongs to the second-generation cephalosporin class, which is known for its broad-spectrum of activity. Its chemical structure provides structural resistance against many bacterial defense enzymes, positioning it as an option for various infections due to its profile.


Q: Does Ceftal have any interactions with birth control pills?

Official documentation for Ceftal notes that the medicine may decrease the effectiveness of certain oral contraceptives. This interaction is described in the official regulatory labeling.


Q: Is it normal to feel nauseous when starting Ceftal?

Nausea and vomiting are listed as Common side effects in the official safety information. These effects, when mild, are sometimes described in health information as being temporary during the initial phase of treatment.


Q: What is the recommended storage temperature for Ceftal?

The tablets must be stored at controlled room temperature, typically 20 C to 25 C, protected from moisture. The reconstituted oral suspension must be stored in the refrigerator (2 C to 8 C) and should not be frozen.


Q: Is there a generic version of Ceftal available?

Yes, the active ingredient in Ceftal, Cefuroxime axetil, is available in generic formulations for the oral tablet dosage form. The availability of the generic form may be determined by the specific dosage form (tablet or suspension) and regulatory approval in a given region.


Q: Are there different strengths of Ceftal tablets?

Yes, the oral tablet formulation of the active ingredient is officially available in strengths of 250 mg and 500 mg. The specific strength prescribed depends on the infection being treated and the patient's individual condition.


Q: Can Ceftal be taken with dairy products?

Official instructions for the oral suspension explicitly state that it must be taken with food, such as milk or milk products, to ensure the medicine is properly absorbed. The tablet formulation may be taken with or without food.


Q: Are there common mental or mood changes linked to Ceftal?

The official safety data lists effects on the nervous system such as headache and dizziness as Common side effects. Mood changes or mental state alterations are not generally listed in the higher frequency categories.


Q: Is it true that Ceftal is used only for severe infections?

Official labeling indicates that Ceftal is used to treat a wide range of infections. This includes conditions described as mild-to-moderate, such as pharyngitis/tonsillitis and uncomplicated urinary tract infections, as well as more severe conditions where parenteral formulations may be utilized.


Q: What is the expiration date on Ceftal based on?

The expiration date (EXP) reflects the time period during which the product is known to remain stable and reliable. This ensures that the medicine retains its required strength, quality, and purity when it is stored exactly according to the labeled storage conditions.


Q: Can Ceftal cause issues with blood sugar levels?

Official safety notes state that Ceftal can interfer with certain laboratory methods used to measure glucose (sugar) in the urine and blood, potentially causing false-positive or false-negative results in these specific tests. The official documentation describes interference with laboratory tests, not a direct alteration of a person's physiological blood sugar levels.


Q: How does Ceftal relate to other cephalosporins?

Ceftal's active ingredient, Cefuroxime, is classified as a second-generation cephalosporin antibiotic. This classification is a descriptive grouping based on the drug's specific spectrum of antibacterial activity and its resistance profile compared to the first- and third-generation antibiotics within the same class.


Q: Does the time of day matter when taking Ceftal?

The standard oral regimen requires the medicine to be taken twice daily, which means approximately every 12 hours. Maintaining this consistent interval between doses (every 12 hours) is a key instruction described in the administration guidelines.

How should Ceftal be stored and disposed of?

How to Store and Dispose of Ceftal?

Ceftal (Cefuroxime Axetil) storage rules differ by dosage form.

Product Form Storage Conditions Stability / In-Use Rule
Tablets Store at controlled room temperature (20 C to 25 C), away from excess heat and moisture. Keep in the original container and blister to protect from moisture. Use before the expiry date (EXP).
Oral Suspension Store the reconstituted liquid in the refrigerator (do not freeze). The container must be kept tightly closed. Discard any unused portion after 10 days of preparation.

All medicine must be kept out of the sight and reach of children.

For disposal, the regulatory label instructs not to throw away Ceftal via wastewater or household waste. Unused or expired medication should be disposed of in accordance with local requirements, typically through a drug take-back program or by asking a pharmacist for guidance on safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ceftal found in:

A-Z Index: